Shortages of two essential cancer drugs have the FDA scrambling to find alternate sources. Supplies of methotrexate to treat childhood leukemia were critically low due to manufacturing problems in the U.S. The FDA has quickly given a German company the green light to provide preservative-free methotrexate. The other drug, doxorubicin, is made by a company in India. The hope is that these imports will cover the shortfall of these crucial chemotherapy agents.
The People's Perspective on Medicine